Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach

Cell Death and Disease

Volumn 7, Issue , 2016, Pages

  Flanagan, L ^a   Meyer, M ^a   Fay, J ^b   Curry, S ^b   Bacon, O ^a,b   Duessmann, H ^a   John, K ^c   Boland, K C ^a   McNamara, D A ^b   Kay, E W ^b   Bantel, H ^c   Schulze Bergkamen, H ^d,e   Prehn, J H M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e MARIEN HOSPITAL WESEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KI 67 ANTIGEN; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CELL REGENERATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TISSUE CULTURE; TISSUE MICROARRAY; TISSUE REGENERATION; TREATMENT RESPONSE; TUNEL ASSAY; COLORECTAL NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; CASPASE 3; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; TISSUE ARRAY ANALYSIS;

EID: 84957561690     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.7     Document Type: Article

References (36)

1. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
2. Rehm M, Dußmann H, Jänicke RU, Tavaré JM, Kögel D, Prehn JHM. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process: role of CASPASE-3. J Biol Chem 2002; 277: 24506-24514.
3. Walsh JG, Cullen SP, Sheridan C, Lüthi AU, Gerner C, Martin SJ. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci 2008; 105: 12815-12819.
4. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351.
5. Martin SJ, Henry CM, Cullen SP. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol Cell 2012; 46: 387-397.
6. Li F, Huang Q, Chen J, Peng Y, Roop DR, Bedford JS et al. Apoptotic cells activate the "Phoenix Rising" pathway to promote wound healing and tissue regeneration. Sci Signal 2010, 3: ra13.
7. Chera S, Ghila L, Dobretz K, Wenger Y, Bauer C, Buzgariu W et al. Apoptotic cells provide an unexpected source of Wnt3 signaling to drive hydra head regeneration. Dev Cell 2009; 17: 279-289.
8. Yamanaka N, Harabuchi Y, Kataura A. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer 1992; 70: 2342-2349.
9. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17: 323-334.
10. Chera S, Ghila L, Dobretz K, Wenger Y, Bauer C, Buzgariu W et al. Apoptotic cells provide an unexpected source of Wnt3 signaling to drive hydra head regeneration. Curr Biol 2009; 19: 1821-1826.
11. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009; 136: 1136-1147.
12. Zhao X, Wang D, Zhao Z, Xiao Y, Sengupta S, Zhang R et al. Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in nonapoptotic ovarian cancer cells. J Biol Chem 2006; 281: 29357-29368.
13. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF et al. Caspase 3-mediated stimulation of tumour cell repopulation during cancer radiotherapy. Nat Med 2011; 17: 860-866.
14. Li F, Huang Q, Chen J, Peng Y, Roop DR, Bedford JS et al. Apoptotic cells activate the "Phoenix Rising" pathway to promote wound healing and tissue regeneration. Sci Signal 2010; 3110: ra13.
15. Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
16. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-1087.
17. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012; 11: 2756-2761.
18. Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18: 3562-3570.
19. Yoshimori A, Sakai J, Sunaga S, Kobayashi T, Takahashi S, Okita N et al. Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacol 2007; 7: 8.
20. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
21. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006; 8: 216.
22. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746.
23. Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci2009; 66: 773-787.
24. Dohadwala M, Yang S-C, Luo J, Sharma S, Batra RK, Huang M et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and Snail in non-small cell lung cancer. Cancer Res 2006; 66: 5338-5345.
25. Boland K, Flanagan F, Prehn JHM. Paracrine control of tissue regeneration and cell proliferation by Caspase-3. Cell Death Dis 2013; 4: e725.
26. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
27. John K, Rosner I, Keilholz U, Gauler T, Bantel H, Grunwald V. Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients. Eur J Cancer 2015; 51: 1596-1602.
28. Seidel N, Volkmann X, Langer F, Flemming P, Manns MP, Schulze-Osthoff K et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005; 42: 113-120.
29. Kim KW, Moretti L, Lu B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS One 2008; 3: e2275.
30. Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A et al. p53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002; 21: 5635-5644.
31. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274: 10911-10915.
32. Vichai V, Suyarnsesthakorn C, Pittayakhajonwut D, Sriklung K, Kirtikara K. Positive feedback regulation of COX-2 expression by prostaglandin metabolites. Inflamm Res 2005; 54: 163-172.
33. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-5505.
34. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005; 11: 725-730.
35. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 2015; 107: 345.
36. Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol 2011; 25: 461-472.